About Tetraphase Pharmaceuticals, Inc.
Tetraphase Pharmaceuticals, Inc. is engaged in the development and production of novel antibiotics for serious and life-threatening bacterial infections. It is currently developing a product candidate, eravacycline, a fully synthetic fluorocycline, as an intravenous and oral antibiotic for use as a first-line empiric monotherapy for the treatment of resistant and multi-drug-resistant infections. The company was founded on July 7, 2006 and is headquartered in Watertown, MA.
At the moment the company generates 17M USD in revenues.
On its last earning announcement, the company reported a loss of -1.37$ per share.
The book value per share is 2.09$
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|